Lenire Biosciences

Lenire Biosciences is a privately held, clinical-stage biopharmaceutical company developing novel, patented treatments for fragile X syndrome (FXS), the leading cause of intellectual disability worldwide, which also manifests as anxiety, attention deficit, hyperactivity, autism spectrum behaviors, and other disabling symptoms.